Ovarian Mucinous Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An invasive adenocarcinoma that arises from the ovary and is characterized by the presence of malignant epithelial cells that contain intracytoplasmic mucin. There is cellular atypia, increased layering of cells, complexity of glands, and papillary formations. 
Ovarian mucinous adenocarcinomas most frequently harbor alterations in KRAS, TP53, CDKN2A, CDKN2B, and SMAD4 .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in ovarian mucinous adenocarcinoma .
There are 4 clinical trials for ovarian mucinous adenocarcinoma, of which 4 are open and 0 are completed or closed. Of the trials that contain ovarian mucinous adenocarcinoma as an inclusion criterion, 1 is early phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open).
BRCA1 and BRCA2 are the most frequent gene inclusion criteria for ovarian mucinous adenocarcinoma clinical trials .
Paclitaxel, carboplatin, and cediranib are the most common interventions in ovarian mucinous adenocarcinoma clinical trials.
Significant Genes in Ovarian Mucinous Adenocarcinoma
BRCA1 is altered in 2.99% of ovarian mucinous adenocarcinoma patients .
BRCA1 is an inclusion eligibility criterion in 1 clinical trial for ovarian mucinous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and ovarian mucinous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
BRCA2 is altered in 8.7% of ovarian mucinous adenocarcinoma patients .
BRCA2 is an inclusion eligibility criterion in 1 clinical trial for ovarian mucinous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and ovarian mucinous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.